Advertisement
U.S. markets closed

EDAP TMS S.A. (EDAP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.01+0.01 (+0.17%)
At close: 04:00PM EST

EDAP TMS S.A.

Parc dActivites la Poudrette-Lamartine
4/6, rue du DauphinE Vaulx-en-Velin
Lyon 69120
France
33 4 72 15 31 50
https://www.edap-tms.com

Sector(s)Healthcare
IndustryMedical Distribution
Full Time Employees264

Key Executives

NameTitlePayExercisedYear Born
Mr. Marc OczachowskiExecutive ChairmanN/AN/A1970
Mr. Ryan RhodesCEO & DirectorN/AN/A1962
Ken MobeckChief Financial OfficerN/AN/AN/A
Mr. Carre EmmanuelChief Operating OfficerN/AN/AN/A
Mr. Francois DietschGlobal Chief Accounting OfficerN/AN/A1976
Ms. Blandine ConfortInvestor Relations Officer & SecretaryN/AN/AN/A
Mr. Frederic PechPresident of EDAP TMS FranceN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. The company serves hospitals, urology clinics, and research institutions. EDAP TMS S.A. was incorporated in 1979 and is headquartered in Lyon, France.

Corporate Governance

EDAP TMS S.A.’s ISS Governance QualityScore as of February 1, 2024 is 10. The pillar scores are Audit: 8; Board: 10; Shareholder Rights: 4; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.